What is William Blair’s Forecast for TWST FY2026 Earnings?

Twist Bioscience Co. (NASDAQ:TWST) – Equities researchers at William Blair issued their FY2026 earnings per share (EPS) estimates for shares of Twist Bioscience in a note issued to investors on Monday, November 18th. William Blair analyst M. Larew anticipates that the company will earn ($1.50) per share for the year. The consensus estimate for Twist Bioscience’s current full-year earnings is ($3.13) per share.

Several other research firms have also weighed in on TWST. Leerink Partners upped their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Barclays reduced their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday. Evercore ISI raised their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Robert W. Baird upped their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.78.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $41.11 on Wednesday. The business’s fifty day moving average price is $43.93 and its two-hundred day moving average price is $46.15. Twist Bioscience has a fifty-two week low of $23.07 and a fifty-two week high of $60.90. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -10.76 and a beta of 1.78.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,730 shares of the stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total value of $81,206.20. Following the transaction, the chief executive officer now owns 495,523 shares of the company’s stock, valued at $23,259,849.62. This represents a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Dennis Cho sold 1,507 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the transaction, the insider now owns 91,163 shares in the company, valued at $4,375,824. This represents a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock worth $4,391,151 over the last 90 days. Insiders own 3.92% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its position in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after buying an additional 526,028 shares during the period. Geode Capital Management LLC increased its stake in Twist Bioscience by 1.9% in the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after purchasing an additional 26,145 shares in the last quarter. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience in the third quarter worth $43,992,000. Wellington Management Group LLP boosted its position in shares of Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares in the last quarter. Finally, Fred Alger Management LLC grew its holdings in shares of Twist Bioscience by 17.1% in the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock valued at $34,660,000 after buying an additional 112,272 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.